Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard D Kim

Showing results (51-60 of 55) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 55 results.
Cancer|June 16, 2018
Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancerHanna K Sanoff, Richard M Goldberg, Anastasia Ivanova, et al.
Cancer|October 13, 2021
Metagenomics and chemotherapy-induced nausea: A roadmap for future researchSylvia L Crowder, Aasha I Hoogland, Taylor L Welniak, et al.
American Journal of Respiratory and Critical Care Medicine|August 16, 2008
Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndromeRichard D Kim, David E Greenberg, Mary E Ehrmantraut, et al.
Cancer Discovery|October 3, 2019
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular CarcinomaRichard D Kim, Debashis Sarker, Tim Meyer, et al.
Hepatology (Baltimore, Md.)|February 2, 2026
Uncovering the genetic landscape of cholangiocarcinoma and its subtypes via GWAS and integrative analysesYounghun Han, Jinyoung Byun, Caitlin J VanLith, et al.
Pageof 6

Showing results (51-60 of 55) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 55 results.
Cancer|June 16, 2018
Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancerHanna K Sanoff, Richard M Goldberg, Anastasia Ivanova, et al.
Cancer|October 13, 2021
Metagenomics and chemotherapy-induced nausea: A roadmap for future researchSylvia L Crowder, Aasha I Hoogland, Taylor L Welniak, et al.
American Journal of Respiratory and Critical Care Medicine|August 16, 2008
Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndromeRichard D Kim, David E Greenberg, Mary E Ehrmantraut, et al.
Cancer Discovery|October 3, 2019
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular CarcinomaRichard D Kim, Debashis Sarker, Tim Meyer, et al.
Hepatology (Baltimore, Md.)|February 2, 2026
Uncovering the genetic landscape of cholangiocarcinoma and its subtypes via GWAS and integrative analysesYounghun Han, Jinyoung Byun, Caitlin J VanLith, et al.
Pageof 6